JP2024504377A5 - - Google Patents
Info
- Publication number
- JP2024504377A5 JP2024504377A5 JP2023544331A JP2023544331A JP2024504377A5 JP 2024504377 A5 JP2024504377 A5 JP 2024504377A5 JP 2023544331 A JP2023544331 A JP 2023544331A JP 2023544331 A JP2023544331 A JP 2023544331A JP 2024504377 A5 JP2024504377 A5 JP 2024504377A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- modified oligonucleotide
- modified
- nucleosides
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163140674P | 2021-01-22 | 2021-01-22 | |
| US63/140,674 | 2021-01-22 | ||
| US202163217624P | 2021-07-01 | 2021-07-01 | |
| US63/217,624 | 2021-07-01 | ||
| US202163231559P | 2021-08-10 | 2021-08-10 | |
| US63/231,559 | 2021-08-10 | ||
| PCT/US2022/013323 WO2022159712A1 (en) | 2021-01-22 | 2022-01-21 | Compounds and methods for reducing dux4 expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024504377A JP2024504377A (ja) | 2024-01-31 |
| JP2024504377A5 true JP2024504377A5 (enExample) | 2025-01-24 |
Family
ID=82549881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023544331A Pending JP2024504377A (ja) | 2021-01-22 | 2022-01-21 | Ｄｕｘ４の発現を低減するための化合物及び方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20240336915A1 (enExample) |
| EP (1) | EP4281084A4 (enExample) |
| JP (1) | JP2024504377A (enExample) |
| WO (1) | WO2022159712A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3830259A4 (en) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| CN117677698A (zh) * | 2021-07-14 | 2024-03-08 | 米雷楚来股份有限公司 | 用于神经肌肉障碍的寡核苷酸及其组合物 |
| WO2023018705A1 (en) * | 2021-08-10 | 2023-02-16 | University Of Massachusetts | Compositions and methods for sirna treatment of muscular dystrophy |
| JP2025532128A (ja) * | 2022-09-23 | 2025-09-29 | アイオーニス ファーマシューティカルズ， インコーポレーテッド | Ｍｅｃｐ２発現を低減する化合物及び方法 |
| JP2025532127A (ja) | 2022-09-23 | 2025-09-29 | アイオーニス ファーマシューティカルズ， インコーポレーテッド | Ｍｅｃｐ２発現を低減する化合物及び方法 |
| US20260159835A1 (en) * | 2024-12-05 | 2026-06-11 | Soufflé Therapeutics, Inc. | Oligonucleotide-mediated knockdown of dux4 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3118316A1 (en) * | 2010-09-02 | 2017-01-18 | Université de Mons | Agents useful in treating facioscapulohumeral muscular dystrophy |
| CA2842798C (en) * | 2011-07-25 | 2021-02-23 | Nationwide Children's Hospital, Inc. | Recombinant virus products and methods for inhibition of expression of dux4 |
| US10538763B2 (en) * | 2015-01-16 | 2020-01-21 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulation of DUX4 |
| EP3353301A1 (en) * | 2015-09-21 | 2018-08-01 | Association Institut de Myologie | Antisense oligonucleotides and uses thereof |
| EP3684378A4 (en) * | 2017-09-19 | 2021-06-16 | Children's National Medical Center | GAPMERS AND THEIR USES IN THE TREATMENT OF MUSCLE DYSTROPHY |
| AU2019218987B2 (en) * | 2018-02-12 | 2025-04-24 | Ionis Pharmaceuticals, Inc. | Modified compounds and uses thereof |
| EP3927827A4 (en) * | 2019-02-22 | 2023-04-26 | Ionis Pharmaceuticals, Inc. | COMPOUNDS AND METHODS FOR REDUCING ATXN3 EXPRESSION |
| TW202104595A (zh) * | 2019-03-29 | 2021-02-01 | 日商田邊三菱製藥股份有限公司 | 用來調節ｄｕｘ４的表現之化合物、方法及醫藥組成物 |
-
2022
- 2022-01-21 US US18/262,438 patent/US20240336915A1/en active Pending
- 2022-01-21 EP EP22743253.1A patent/EP4281084A4/en active Pending
- 2022-01-21 JP JP2023544331A patent/JP2024504377A/ja active Pending
- 2022-01-21 WO PCT/US2022/013323 patent/WO2022159712A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020193199A5 (enExample) | ||
| JP2024520205A5 (enExample) | ||
| JP2022515193A5 (enExample) | ||
| JP2021530204A5 (enExample) | ||
| JP5650367B2 (ja) | 医薬組成物 | |
| JP2022520986A5 (enExample) | ||
| TWI881004B (zh) | 用於治療ｈｂｖ之靶向ｈｂｖ的治療性寡核苷酸及ｔｌｒ７促效劑之醫藥組合 | |
| CN100400045C (zh) | 基于核酸的化合物及其使用方法 | |
| JP2023537798A5 (enExample) | ||
| JPH07300493A (ja) | ２′−エーテル基を有する、ヌクレオシド及びオリゴヌクレオチド | |
| TW201803989A (zh) | 拮抗ｂ型肝炎病毒之組成物和藥劑及彼等之用途 | |
| JP2022518929A5 (enExample) | ||
| JP2022527105A5 (enExample) | ||
| JPH11511014A (ja) | 免疫刺激応答が低減した遺伝子発現の調節法 | |
| JP2021072862A (ja) | Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子 | |
| JP2023500661A5 (enExample) | ||
| JP2023536472A5 (enExample) | ||
| JP2023549563A5 (enExample) | ||
| JP2024504377A (ja) | Ｄｕｘ４の発現を低減するための化合物及び方法 | |
| JP2024523363A5 (enExample) | ||
| JP2023530072A5 (enExample) | ||
| JP2023543215A5 (enExample) | ||
| JP2025039668A (ja) | Ｒｔｅｌ１発現の調節用のオリゴヌクレオチド | |
| JP2024506351A5 (enExample) | ||
| KR20240101580A (ko) | Hbv 치료를 위한 약학 조합물 |